Nideolo (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 cellular pathway, which increases antioxidant defenses and reduces inflammatory signaling. This leads to modulation of immune cell activity, providing neuroprotective and anti‑inflammatory effects that are beneficial in multiple sclerosis and psoriasis.

The specific dose and titration schedule for Nideolo are determined by the prescribing clinician based on the patient’s condition, weight, and response. The product is supplied as a prescription‑only medication, and dosing should follow the prescriber’s instructions.

Safety data for dimethyl fumarate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting therapy.

To request Nideolo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with injectable disease‑modifying therapies, dimethyl fumarate is an oral option that offers convenient administration and a distinct mechanism via Nrf2 activation. Its efficacy in reducing relapse rates is comparable to some injectables, while its safety profile includes a higher incidence of flushing and gastrointestinal effects.

Nideolo should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Nideolo is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

The most serious risks include severe lymphopenia, which can predispose to opportunistic infections, and the rare but potentially fatal condition progressive multifocal leukoencephalopathy (PML). Regular monitoring of blood counts and vigilance for signs of infection are essential during treatment.

Patients with known hypersensitivity to dimethyl fumarate or any of its excipients should avoid Nideolo. It is also contraindicated in individuals with active, serious infections or those receiving live vaccines, and caution is advised for patients with severe hepatic impairment.